Raghu Mudumbai is an Ophthalmology physician affiliated with University of Washington Medical Center. OpenAlex indexes 72 publications with 938 citations (h-index 14); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
University Of Washington Medical Ctr
1959 NE Pacific St
Seattle, WA 981956485
Telephone
206-731-3225Registry record last updated 25 Jan 2012.
Clinical trials
- Use of Nanodropper vs. Standard Eyedropper in Patients With Glaucoma and Ocular Hypertension
Sponsor: University of Washington
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ARGENX US, INC.Program year20251 payment
- Amgen Inc.Program year20241 payment
- Alexion Pharmaceuticals, Inc.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
72.2%Prostaglandin Analog30.8%Latanoprost90%Lumigan10%Part D≥145 patientsalpha-Adrenergic Agonist16.1%Brimonidine Tartrate92%Alphagan P4%Brimonidine Tartrate-Timolol3%Part D<11 patients+ 4 more classes in this area
Cardiovascular
19.8%Beta blocker19.2%Timolol Maleate100%Part D≥97 patientsBlood Viscosity Reducer0.6%Pentoxifylline100%Part D<11 patientsMusculoskeletal
4.3%Cyclooxygenase Inhibitor4.3%Ketorolac Tromethamine100%Part D≥42 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- In-vivo characterization of scleral rigidity in myopic eyes using fundus-pulsation optical coherence elastography
Biomedical Optics Express
2024 - Feature compression is the root cause of adversarial fragility in neural network classifiers
arXiv (Cornell University)
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Ganesh Raghu, MD
University of Washington Medical Center
Ali Samii
University of Washington Medical Center
Mark Wener
University of Washington Medical Center
Creighton Don, MD, PhD
University of Washington Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”